12月24日，A股市场早盘窄幅震荡，三大指数集体翻红。截至午盘，沪指涨0.24%，深成指涨0.31%，创 业板指涨0.08%。沪深两市半日成交额1.16万亿，较上个交易日缩量895亿。全市场超3800只个股上涨。 | 名称 | 现价 | 涨跌 | 涨跌幅 | 成交额 | | --- | --- | --- | --- | --- | | 上证指数 | 3929.25 | 9.27 | 0.24% | 4659亿 | | 深证成指 | 13410.05 | 41.06 | 0.31% | 6828亿 | | 万得全A | 6345.55 | 30.17 | 0.48% | 11592亿 | | 科创综指 | 1615.07 | 12.48 | 0.78% | 1171亿 | | 创业板指 | 3207.59 | 2.58 | 0.08% | 3083亿 | | 北证50 | 1442.57 | 2.63 | 0.18% | 106亿 | 从板块来看，商业航天概念持续走强，近20只成分股涨停，其中超捷股份20cm涨停，神剑股份5连板， 九鼎新材、合众思壮、再升科技涨停。消息面上，据证监会网上办事服务平台披露，近日 ...

Core Viewpoint - The company Hansai Aitai-B (03378) has seen a rebound of nearly 6%, with a current increase of 5.12%, trading at HKD 18.08, and a transaction volume of HKD 10.4874 million [1] Group 1: Clinical Development - The company announced that its innovative drug, HX111, has been approved by the National Medical Products Administration of the People's Republic of China to conduct clinical trials within China [1] - HX111 is a first-in-class OX40-targeted antibody-drug conjugate (ADC), which has shown overexpression in several malignant tumors compared to normal tissues during preclinical studies, making it a suitable target for ADC [1] - HX111 is the third first-in-class molecule to advance to clinical development, following HX009 and HX044, both of which are bispecific antibody therapies [1] Group 2: Future Plans - The company aims to continue its efforts in clinical development to bring more novel first-in-class drugs to market [1]

Core Viewpoint - The company Hansa Biopharma-B (03378) has seen a nearly 6% rebound in its stock price following the approval of its innovative drug HX111 for clinical trials in China by the National Medical Products Administration [1] Group 1: Company Developments - Hansa Biopharma announced that its innovative drug injection HX111 has been approved for clinical trials in China [1] - HX111 is a first-in-class OX40-targeted antibody-drug conjugate (ADC), which has shown overexpression in several malignancies compared to normal tissues, making it a suitable target for ADC [1] - HX111 is the third first-in-class molecule to advance to clinical development, following HX009 and HX044, both of which are bispecific antibody therapies [1] Group 2: Market Reaction - Following the announcement, Hansa Biopharma's stock price increased by 5.12%, reaching HKD 18.08, with a trading volume of HKD 10.4874 million [1]

Group 1 - The core viewpoint of the news is that Taiankang's stock has shown significant fluctuations, with a year-to-date increase of 88.70% and a recent decline over the past 60 days of 18.68% [1] - As of December 24, Taiankang's stock price was 27.91 yuan per share, with a market capitalization of 11.876 billion yuan [1] - The company has seen a net inflow of main funds amounting to 1.1218 million yuan, with large orders accounting for 14.42% of total buying [1] Group 2 - For the period from January to September 2025, Taiankang reported a revenue of 526 million yuan, a year-on-year decrease of 8.13%, and a net profit attributable to shareholders of 31.4052 million yuan, down 73.00% year-on-year [2] - The number of shareholders increased by 9.32% to 12,000, while the average circulating shares per person decreased by 8.53% to 25,381 shares [2] - Since its A-share listing, Taiankang has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [3]

Core Viewpoint - Rongchang Biopharmaceuticals has shown significant stock price growth this year, but recent trading data indicates a decline in the short term, raising questions about future performance and investor sentiment [1][3]. Group 1: Stock Performance - As of December 24, Rongchang Biopharmaceuticals' stock price increased by 2.07% to 81.76 CNY per share, with a market capitalization of 46.09 billion CNY [1]. - The stock has risen 171.54% year-to-date, but has experienced a decline of 0.17% over the last five trading days, 11.37% over the last 20 days, and 20.83% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent instance on June 26, where it recorded a net buy of -137 million CNY [1]. Group 2: Company Overview - Rongchang Biopharmaceuticals, established on July 4, 2008, and listed on March 31, 2022, is based in Yantai, Shandong, China, focusing on innovative biopharmaceuticals, particularly in antibody-drug conjugates (ADC) and therapeutic antibodies [2]. - The company aims to develop first-in-class and best-in-class biopharmaceuticals to address significant unmet clinical needs in autoimmune diseases, oncology, and ophthalmology [2]. - The revenue composition shows that 99.46% comes from product sales, with minimal contributions from material sales and leasing services [2]. Group 3: Financial Performance - For the period from January to September 2025, Rongchang Biopharmaceuticals reported revenue of 1.72 billion CNY, reflecting a year-on-year growth of 42.27%, while the net profit attributable to shareholders was -551 million CNY, an increase of 48.60% year-on-year [3]. Group 4: Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 18.33% to 15,300, with an average of 10,639 circulating shares per person, down 15.54% from the previous period [3]. - The second-largest shareholder is Hong Kong Central Clearing Limited, holding 8.84 million shares, a decrease of 510,800 shares from the previous period [4]. - Other notable shareholders include Wanjiayou Selected and Industrial Bank Frontier Medical Stock A, with varying changes in their holdings [4].

Group 1: Market Trends - Public funds are increasingly viewing Hong Kong stocks as a core layout direction for year-end investment, with over ten public funds recently applying for thematic funds focused on technology, consumption, and dividends [1] - The A-share market showed mixed performance on December 23, with the Shanghai Composite Index closing at 3919.98 points, up 0.07%, while nearly 3900 stocks in the market declined [1] Group 2: Fund News - On December 23, two new mixed funds were launched, with Ping An Digital Economy Select Mixed A aiming to raise 500 million yuan [2] - The net inflow for A500-related ETFs has exceeded 60 billion yuan in December, indicating strong market demand for this index as a preferred broad-based investment tool [2] - As of December 19, insurance institutions have contributed 109.76 billion yuan to private equity funds, marking a 55.85% increase year-on-year, driven by macroeconomic factors and regulatory encouragement [2] Group 3: Future Outlook - Fund managers from major public funds are optimistic about 2026, expecting a shift from valuation-driven market dynamics to a dual drive of "profitability + valuation" [3] - Key investment themes for the upcoming year include AI technology, innovative pharmaceuticals, and domestic consumption recovery, with a focus on high-dividend defensive stocks and cyclical recovery [3]

Group 1 - Multiple fund managers remain optimistic about the equity market for the upcoming year, discussing investment opportunities in AI technology, consumption, and innovative pharmaceuticals during recent strategy meetings [1][17] - Sunac China has completed a comprehensive overseas debt restructuring, relieving approximately $9.6 billion in existing debt and significantly reducing overall repayment pressure by nearly 60 billion yuan [2][18] - The listing of Easy Health Group on the Hong Kong Stock Exchange saw its stock price surge by 158.82% on the first day, achieving a market capitalization of 12.1 billion HKD, marking it as one of the few profitable digital health companies [4][20] Group 2 - The Ministry of Housing and Urban-Rural Development emphasizes the significant growth potential in the real estate sector during the national housing and urban construction work conference [8][25] - The central economic work conference calls for the formulation and implementation of further deepening state-owned enterprise reforms in 2026, indicating a new cycle of reform [9][26] - The recent strengthening of the RMB, nearing the 7.0 mark against the USD, is attributed to positive economic data and increased willingness among exporters to convert their earnings [10][27] Group 3 - National Pension Insurance Co. is undergoing a second round of capital increase, with a total amount of 500 million yuan planned, reflecting a 20% increase in share value compared to the previous year [11][28] - The securities industry is expected to continue its transformation, focusing on differentiated development and enhancing operational efficiency as it moves towards 2025 [12][29][30] - The Chinese government is implementing more proactive fiscal and monetary policies to stabilize employment, businesses, and market expectations, aiming for sustained economic recovery [13][31]

Group 1 - The core viewpoint of the articles highlights the rapid growth and high-quality development of China's innovative pharmaceutical industry, with 69 innovative drugs approved in 2025, surpassing the previous year's total of 48, marking a historical high [1] - China's pharmaceutical industry is now the second largest globally, with approximately 30% of the world's innovative drugs in development [1] - The industry is expected to maintain high-speed growth through 2026, with increased R&D investment and a shift towards profitability for more companies, particularly in key areas like ADC, bispecific antibodies, and CGT [1] Group 2 - In 2025, the value of business development (BD) transactions in China's innovative drug sector is projected to exceed $100 billion, indicating a shift from mere scale expansion to value enhancement [2] - China has become the largest source of licensing globally, with 90% of the top 20 multinational pharmaceutical companies collaborating with Chinese innovative drug pipelines [2] - However, the proportion of first-in-class (FIC) drugs remains low, and most BD activities are still concentrated in early-stage licensing, which limits potential future revenues [2][3] Group 3 - The current low pricing of Chinese biotech assets in overseas transactions is attributed to several factors, including the predominance of early-stage licensing and the need for additional validation of clinical data [4] - The Co-Co model, which involves shared development costs, is not expected to become mainstream in the short term due to the financial pressures on companies, although it is gaining traction among leading firms [5] Group 4 - The Hong Kong stock market remains a key listing venue for unprofitable biotech companies, with IPO financing in the healthcare sector leading globally and over 60% of shares held by international institutional investors [6] - The valuation focus for Hong Kong-listed innovative drug companies is shifting towards BD capabilities, clinical progress, and global commercialization potential [8] Group 5 - Future investment trends in China's innovative drug sector are expected to emphasize high technical barriers and commercialization potential, with a move away from follow-on innovation projects [12] - The BD capabilities will become a core valuation anchor, with transaction models evolving from single rights buyouts to more collaborative approaches [12]

● 本报记者 魏昭宇 近期，国泰基金、招商基金、汇丰晋信基金、长城基金等多家公募机构召开了2026年度策略会，多位基 金经理围绕AI科技、消费、创新药等热门板块的后续投资机遇展开深度探讨。 展望2026年，有业内人士表示，市场值得乐观期待，上涨动力或将从单一的估值驱动逐渐转向"盈利 +估值"双重驱动。2026年作为"十五五"开局之年，相关产业政策及宏观经济支持政策值得期待。明年上 市公司整体业绩有望进一步改善，结构性亮点大概率增多，有利于提高市场风险偏好。当前A股自由流 通市值与居民存款的比值仍然处于相对较低的水平，股票市场或迎来更多新增资金。此外，当前市场估 值结构较为健康，并未出现整体过热的情况。 企业整体业绩大概率提升 从宏观层面来看，招商基金研究部首席经济学家李湛认为，中国经济增长模式逐渐转向创新驱动，基建 和高技术产业拉动经济增长。权益方面，市场目前开启了一轮估值修复与资产轮动逻辑驱动的行情。综 合来看，2026年消费有望缓慢抬升，出口有韧性，商品价格温和走高，进而带动名义GDP上行，企业业 绩或持续修复，这将成为市场的基本面支撑。A股行情或逐渐过渡至公司业绩支撑的"缓而慢"的格局。 国泰基金宏观策 ...

Group 1 - The A-share market has achieved a historic milestone with an annual trading volume exceeding 400 trillion yuan, indicating increased market activity and attractiveness of the Chinese capital market [1] - As of December 23, the total trading volume for the year reached over 407 trillion yuan, with four instances of daily trading volumes surpassing 3 trillion yuan [1] - Key stocks driving market growth include 19 stocks with trading volumes exceeding 1 trillion yuan, with notable performers like Zhongji Xuchuang and Dongfang Caifu exceeding 2 trillion yuan [1] Group 2 - International capital inflow has accelerated, with a net inflow of $5.51 billion into the Chinese market from October 30 to November 26, compared to $1.57 billion during the same period last year [2] - The quality of companies is improving, which is crucial for enhancing market activity; projected earnings growth for all A-shares is expected to rise from 8.2% in 2025 to 10.3% in 2026 [2] - The ChiNext and Sci-Tech Innovation Board are expected to maintain high growth rates, with projected earnings growth of 31.7% and 34.3% respectively in 2026 [2] Group 3 - Looking ahead to 2026, global capital rebalancing is anticipated to bring in new overseas funds, positively impacting emerging markets including A-shares [3] - The industry allocation in the A-share market is expected to shift from a narrow focus to a broader competitive landscape, with recommendations to focus on AI, new energy, military industry, and innovative pharmaceuticals [3] - The investment strategy should evolve from a focus on stable dividends to a combination of dividends and growth potential, emphasizing "free cash flow" [3]